4564 — OncoTherapy Science Income Statement
0.000.00%
Last trade - 00:00
- ¥10bn
- ¥9bn
- ¥610m
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Yuho | Yuho | Yuho | Yuho | Yuho |
Standards: | JAS | JAS | JAS | JAS | JAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 316 | 332 | 1,154 | 1,135 | 610 |
Cost of Revenue | |||||
Gross Profit | -50.1 | 19.5 | 114 | 41.7 | -178 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 2,596 | 1,891 | 3,705 | 2,225 | 1,880 |
Operating Profit | -2,280 | -1,559 | -2,551 | -1,090 | -1,270 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -2,237 | -1,560 | -2,570 | -1,116 | -1,286 |
Provision for Income Taxes | |||||
Net Income After Taxes | -2,239 | -1,562 | -2,572 | -1,119 | -1,288 |
Net Income Before Extraordinary Items | |||||
Net Income | -2,239 | -1,562 | -2,572 | -1,119 | -1,288 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -2,239 | -1,562 | -2,572 | -1,119 | -1,288 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -13.6 | -9.15 | -12 | -5.86 | -5.6 |
Dividends per Share |